VR Logo

Cullinan Oncology Inc. (CGEM) download report


Healthcare | Biotechnology & Pharma Research

Cullinan Oncology Inc. (CGEM) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States.

IPO Date: 08-Jan-2021

Pres, CEO & Director: Mr. Nadim Ahmed

CFO & Treasurer: Mr. Jeffrey Trigilio

Listing: NASDAQ: CGEM

Country: United States

Headquarters: Cambridge, MA

Website: https://www.cullinanoncology.com

Key Facts

Market cap: $557.54 Mln

Revenue (TTM): $-18.92 Mln

Earnings (TTM): $-77.60 Mln

Cash: $314.85 Mln

Total Debt: $2.06 Mln

Insider's Holding: 17.97%

Liquidity: Low

52 Week range: $7.30 - 30.33

Shares outstanding: 44,782,500

10 Years Aggregate:

  • CFO: $-108.71 Mln
  • EBITDA: $-97.03 Mln
  • Net Profit: $-87.97 Mln

Stock Performance

Time Period Cullinan Oncology (CGEM) S&P BSE Sensex* S&P Small-Cap 600*
YTD-19.64-8.46-19.22
1 month8.01-2.84-9.34
3 months10.71-7.97-14.58
1 Year-52.601.48-17.64
3 Years--10.625.91
5 Years--11.565.64
10 Years--11.8310.10
As on 29-Jun-2022 *As on 30-Jun-2022